Cargando…
TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats
In hypertensive subjects, angiotensin II and endothelin participate in a manner involving closely interwoven pathways in increasing blood pressure (BP) and inducing end organ damage. The primary objective of this study was to determine the effect of TRC120038, a novel dual AT(1)/ET(A) receptor block...
Autores principales: | Mohanan, Anookh, Gupta, Ram, Dubey, Amita, Jagtap, Vikrant, Mandhare, Appaji, Gupta, Ramesh C., Chauthaiwale, Vijay, Dutt, Chaitanya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253485/ https://www.ncbi.nlm.nih.gov/pubmed/22235363 http://dx.doi.org/10.4061/2011/751513 |
Ejemplares similares
-
TRC150094 attenuates progression of nontraditional cardiovascular risk factors associated with obesity and type 2 diabetes in obese ZSF1 rats
por: Zambad, Shitalkumar P, et al.
Publicado: (2011) -
Safety, Tolerability, and Pharmacokinetics of a Novel Mitochondrial Modulator, TRC150094, in Overweight and Obese Subjects: A Randomized Phase-I Clinical Trial
por: Joshi, Deepa, et al.
Publicado: (2021) -
Therapeutic treatment with a novel hypoxia-inducible factor hydroxylase inhibitor (TRC160334) ameliorates murine colitis
por: Gupta, Ram, et al.
Publicado: (2014) -
TRC150094, a Novel Mitochondrial Modulator, Reduces Cardio-Metabolic Risk as an Add-On Treatment: a Phase-2, 24-Week, Multi-Center, Randomized, Double-Blind, Clinical Trial
por: Joshi, Deepa, et al.
Publicado: (2022) -
TRC210258, a novel TGR5 agonist, reduces glycemic and dyslipidemic cardiovascular risk in animal models of diabesity
por: Zambad, Shitalkumar P, et al.
Publicado: (2013)